CareDx Inc
NASDAQ:CDNA
Intrinsic Value
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. [ Read More ]
The intrinsic value of one CDNA stock under the Base Case scenario is 12.81 USD. Compared to the current market price of 8.31 USD, CareDx Inc is Undervalued by 35%.
Valuation Backtest
CareDx Inc
Run backtest to discover the historical profit from buying and selling CDNA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CareDx Inc
Current Assets | 313.7m |
Cash & Short-Term Investments | 235.4m |
Receivables | 51.1m |
Other Current Assets | 27.2m |
Non-Current Assets | 153.1m |
PP&E | 65.1m |
Intangibles | 86m |
Other Non-Current Assets | 1.9m |
Current Liabilities | 78.1m |
Accounts Payable | 12.9m |
Accrued Liabilities | 35.4m |
Other Current Liabilities | 29.8m |
Non-Current Liabilities | 127.4m |
Other Non-Current Liabilities | 127.4m |
Earnings Waterfall
CareDx Inc
Revenue
|
280.3m
USD
|
Cost of Revenue
|
-102m
USD
|
Gross Profit
|
178.3m
USD
|
Operating Expenses
|
-282.4m
USD
|
Operating Income
|
-104m
USD
|
Other Expenses
|
-86.2m
USD
|
Net Income
|
-190.3m
USD
|
Free Cash Flow Analysis
CareDx Inc
What is Free Cash Flow?
CDNA Profitability Score
Profitability Due Diligence
CareDx Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
CareDx Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CDNA Solvency Score
Solvency Due Diligence
CareDx Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
CareDx Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDNA Price Targets Summary
CareDx Inc
According to Wall Street analysts, the average 1-year price target for CDNA is 12.65 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.
Ownership
CDNA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CDNA Price
CareDx Inc
Average Annual Return | 27.26% |
Standard Deviation of Annual Returns | 142.61% |
Max Drawdown | -95% |
Market Capitalization | 428m USD |
Shares Outstanding | 53 388 830 |
Percentage of Shares Shorted | 13.2% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in South San Francisco, California and currently employs 633 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. The company develops and provides diagnostic surveillance testing services for various transplant recipients.
Contact
IPO
Employees
Officers
The intrinsic value of one CDNA stock under the Base Case scenario is 12.81 USD.
Compared to the current market price of 8.31 USD, CareDx Inc is Undervalued by 35%.